These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20812904)

  • 1. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
    Wang XK; Fu LW
    Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversing multidrug resistance by tyrosine kinase inhibitors.
    He M; Wei MJ
    Chin J Cancer; 2012 Mar; 31(3):126-33. PubMed ID: 22237041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
    Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
    Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
    Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
    Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
    Deng J; Shao J; Markowitz JS; An G
    Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.
    Anreddy N; Gupta P; Kathawala RJ; Patel A; Wurpel JN; Chen ZS
    Molecules; 2014 Sep; 19(9):13848-77. PubMed ID: 25191874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
    Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S; Robey RW; Bates SE; Ambudkar SV
    Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.
    Krchniakova M; Skoda J; Neradil J; Chlapek P; Veselska R
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
    Wu S; Fu L
    Mol Cancer; 2018 Feb; 17(1):25. PubMed ID: 29455646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
    Mohammad IS; He W; Yin L
    Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
    Lemos C; Jansen G; Peters GJ
    Br J Cancer; 2008 Mar; 98(5):857-62. PubMed ID: 18253130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
    Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
    Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of multidrug resistance in the age of targeted therapy.
    Türk D; Szakács G
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.